Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CellDesign Inc.

This article was originally published in Start Up

Executive Summary

Current cellular models for drug discovery can be notoriously unreliable, both for their predictive power and their sustainability. Cells derived from human progenitor stem cells can provide homogeneity over countless experiments, but working with them remains a complex scientific art. By industrializing production of stem cell-derived cell model systems, CellDesign Inc. intends to capture a chunk of the existing $1.5 billion market for cellular model systems and grow it through sales of easy-to-use kits for deriving everything from human fat cells to Alzheimer's disease-ridden neurons.

You may also be interested in...



Amorcyte Inc.

Amorcyte is intent on developing patients' own enriched bone-marrow stem cells as a treatment for cardiovascular disease. The idea is to infuse the stem cells into the heart a week or so after a severe heart attack, where they will linger and help restore damaged tissue. Results of a Phase I clinical trial recently reported at the scientific session of the American College of Cardiology conference showed the treatment was safe, and yielded insight into the minimum dosage necessary to generate a beneficial effect.

California Stem Cell Inc.

California Stem Cell Inc.'s founder, Hans S. Keirstead, PhD, is well known in stem cell circles as the developer of processes that can produce extremely pure cell lines from human embryonic stem cells. As such, the start-up is uniquely situated. Not only does it produce over 95% pure populations of several cell types for use in research, but the firm also has proprietary reagents it sells to pharma and biotech firms. And it is building its own therapeutic pipeline: CSC is poised to file an IND for an hESC-derived therapy to treat type 1 infantile spinal muscular atrophy, the largest genetic killer of children under the age of two.

Cardio3 Biosciences SA

In March 2009, Belgium's Cardio3 BioSciences announced that a patient with chronic heart failure had for the first time received its C-Cure, a stem cell-based therapy developed to help heal damaged heart tissue. The procedure involved transplantation of the patient's own bone-marrow cells, which had been cultured and implanted according to specialized protocols. The company claims it has proved that its cells become cardiac myocytes, and are also part of the new vessels that are generated post-therapy. The Cardio3's scientists could also demonstrate that the implanted cells did not cause arrhythmia and thus were electrically linked to the rest of the tissue in the heart.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC091771

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel